Investors Shouldn't Be Too Comfortable With Youngy Health's (SZSE:300247) Earnings
Investors Shouldn't Be Too Comfortable With Youngy Health's (SZSE:300247) Earnings
Despite posting some strong earnings, the market for Youngy Health Co., Ltd.'s (SZSE:300247) stock hasn't moved much. Our analysis suggests that shareholders have noticed something concerning in the numbers.
儘管融捷健康有限公司(SZSE:300247)發佈了一些強勁的收益,但股票市場並沒有出現太大波動。我們的分析表明,股東們已經注意到數字中的一些令人擔憂的地方。

The Impact Of Unusual Items On Profit
除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。
To properly understand Youngy Health's profit results, we need to consider the CN¥16m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that Youngy Health's positive unusual items were quite significant relative to its profit in the year to June 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.
爲了正確理解融捷健康的利潤結果,我們需要考慮到歸因於飛凡項目的1600萬人民幣收益。雖然利潤增加總是令人愉悅的,但來自飛凡項目的巨額貢獻有時會減弱我們的熱情。當我們分析了全球大多數上市公司時,發現重要的飛凡項目通常不會重複出現。這符合預期,因爲這些提振被描述爲「飛凡」。我們可以看到,融捷健康在2024年6月的年度利潤中,來自飛凡項目的正面影響相當顯著。其他條件相同的情況下,這可能會導致法定利潤成爲衡量基本盈利能力的一個不良指標。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Youngy Health.
注:我們始終建議投資者檢查資產負債表的實力。點擊這裏查看我們對融捷健康的資產負債表分析。
Our Take On Youngy Health's Profit Performance
我們對融捷健康的利潤表現的看法
As previously mentioned, Youngy Health's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that Youngy Health's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But the happy news is that, while acknowledging we have to look beyond the statutory numbers, those numbers are still improving, with EPS growing at a very high rate over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. While conducting our analysis, we found that Youngy Health has 1 warning sign and it would be unwise to ignore it.
正如先前提到的,融捷健康受益於飛凡項目的大幅提升,但這種情況不會永遠持續,因此其法定收益可能不是評估其潛在盈利能力的良好指南。因此,我們認爲融捷健康的法定利潤可能不是公司潛在收益能力的良好指引,並可能使投資者對公司產生過分樂觀的印象。但令人高興的消息是,儘管我們知道必須超越法定數字來思考,這些數字仍在改善,每股收益在過去一年增長速度非常快。本文的目標是評估我們可以多大程度上依賴法定收益來反映公司的潛力,但還有很多要考慮的地方。因此,如果您想更深入地了解這支股票,考慮到它面臨的任何風險是至關重要的。在進行分析時,我們發現融捷健康有一個警示信號,如果忽視它將是不明智的。
This note has only looked at a single factor that sheds light on the nature of Youngy Health's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
本文僅着眼於一項能揭示融捷健康利潤性質的單一因素。但還有許多其他方法可以形成對公司的看法。例如,許多人認爲股東權益回報率高是良好業務經濟的指示,而其他人則喜歡「追蹤資金」並尋找內部人員在購買的股票。因此,您可能希望查看這些擁有高股東權益回報率的公司自由收集,或者這些擁有高內部所有權的股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。